Efficacy of Losartan in Preventing Progression of COPD
Information source: National Heart, Lung, and Blood Institute (NHLBI)
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: COPD; Emphysema; Chronic Bronchitis; Smoking
Intervention: Losartan (Drug); Placebo (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI) Official(s) and/or principal investigator(s):
Robert A. Wise, MD, Principal Investigator, Affiliation: Johns Hopkins University
Overall contact:
Gwen Leatherman, RN, Phone: 410 550-0800, Email: gleathe@jhmi.edu
Summary
Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage
due to smoking. The goal of this study is to determine whether this drug which is also used
to treat hypertension can stabilize or improve lung function in people who have from chronic
obstructive pulmonary disease (COPD).
Clinical Details
Official title: Efficacy of Losartan in Preventing Progression of COPD
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Extent of emphysema on CT scan
Secondary outcome: Pulmonary function testing
Detailed description:
Participants will be given either losartan in a dose of 50-100 mg per day for a period of
one year. During that time, they will have lung function tests, breathing tests, and
computed tomograms of the chest. These tests will determine whether there is inflammation
in the lung and whether there is progressive involvement of the lung with COPD.
Eligibility
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adults with COPD who are either active or former smokers
Exclusion Criteria:
- Clinical requirement or history of intolerance of angiotensin receptor blockers,
serious heart, liver, kidney, neurological disease.
Locations and Contacts
Gwen Leatherman, RN, Phone: 410 550-0800, Email: gleathe@jhmi.edu
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland 21205, United States; Recruiting
Teresa Concordia, RN, Phone: 410-283-5728, Email: tconcor1@jhmi.edu
Robert A. Wise, MD, Principal Investigator
Enid Neptune, MD, Sub-Investigator
Nadia Hansel, MD, Sub-Investigator
Gregory Diette, MD, Sub-Investigator
M. Bradley Drummond, MD, Sub-Investigator
Additional Information
Starting date: July 2008
Ending date: August 2012
Last updated: July 18, 2008
|
